William C Cushman

Author PubWeight™ 383.09‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 97.28
2 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 63.78
3 Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 47.90
4 Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010 21.49
5 A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015 19.14
6 Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 16.40
7 Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010 10.75
8 Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007 9.62
9 Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010 9.20
10 Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013 8.74
11 Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011 8.14
12 Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008 6.96
13 Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002 6.03
14 Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008 5.26
15 Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007 4.21
16 Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005 3.89
17 Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med 2013 2.74
18 Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 2008 2.51
19 Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med 2015 2.42
20 Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2012 2.42
21 Diabetes and hypertension: the bad companions. Lancet 2012 2.10
22 ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009 2.02
23 Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005 1.99
24 Antihypertensive prescriptions for newly treated patients before and after the main antihypertensive and lipid-lowering treatment to prevent heart attack trial results and seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure guidelines. Hypertension 2009 1.92
25 Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int 2011 1.91
26 Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006 1.73
27 Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care 2013 1.71
28 Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Arch Intern Med 2010 1.64
29 Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes 2012 1.59
30 Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med 2010 1.57
31 Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care 2012 1.55
32 Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation 2011 1.52
33 Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension 2008 1.46
34 Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans. Am J Nephrol 2015 1.42
35 Hypertension and heart failure. Roundtable discussion. J Clin Hypertens (Greenwich) 2004 1.38
36 The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. Am Heart J 2007 1.33
37 Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone. Curr Control Trials Cardiovasc Med 2002 1.13
38 Disparity implications of Medicare eligibility criteria for medication therapy management services. Health Serv Res 2010 1.09
39 The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005 1.02
40 Hypertension in adults across age groups. JAMA 2005 0.96
41 Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich) 2012 0.95
42 Hypertension control among newly treated patients before and after publication of the main ALLHAT results and JNC 7 guidelines. J Clin Hypertens (Greenwich) 2012 0.95
43 Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2007 0.95
44 EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J 2011 0.94
45 Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich) 2006 0.94
46 Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria. Res Social Adm Pharm 2013 0.91
47 Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med 2012 0.91
48 Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex. Hypertension 2013 0.90
49 Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 2002 0.89
50 Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc 2006 0.87
51 Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project. Clin Trials 2009 0.86
52 Chlorthalidone versus hydrochlorothiazide. Ann Intern Med 2013 0.86
53 Response to six classes of antihypertensive medications by body mass index in a randomized controlled trial. J Clin Hypertens (Greenwich) 2003 0.84
54 New recommendations for treating hypertension in black patients: evidence and/or consensus? Hypertension 2010 0.83
55 Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements? Eur Heart J 2012 0.83
56 National utilization of antihypertensive medications from 2000 to 2006 in the Veterans Health Administration: focus on thiazide diuretics. J Clin Hypertens (Greenwich) 2008 0.82
57 Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups. J Manag Care Spec Pharm 2015 0.77
58 Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs. either monotherapy: ValVET primary results. J Clin Hypertens (Greenwich) 2011 0.77
59 ACC/AHA Special Report: Clinical Practice Guideline Implementation Strategies: A Summary of Systematic Reviews by the NHLBI Implementation Science Work Group: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017 0.76
60 The treatment of hypertension in the elderly. J Clin Hypertens (Greenwich) 2008 0.76
61 Systolic hypertension in the elderly. Postgrad Med 1993 0.75
62 Control of blood pressure: does it matter which agent you use? J Clin Hypertens (Greenwich) 2007 0.75
63 Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity. Cardiovasc Drugs Ther 2012 0.75
64 Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy. Blood Press Monit 2011 0.75
65 Descriptive characteristics and cluster analysis of male veteran hazardous drinkers in an alcohol moderation intervention. Am J Addict 2012 0.75
66 How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure? Stat Med 2012 0.75
67 Association between chronic kidney disease and cancer mortality: A report from the ALLHAT. Clin Nephrol 2016 0.75
68 Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease. Am J Nephrol 2016 0.75
69 What should our blood pressure goal be in patients with diabetes? J Clin Hypertens (Greenwich) 2007 0.75